Washington, DC - Tuesday, the American Diabetes Association’s (ADA’s) Chief Scientific, Medical and Mission Officer William T. Cefalu, MD, testified before the U.S. Senate Special Committee on Aging (Committee). Dr. Cefalu addressed the Committee and answered questions about the rising costs of insulin, which impacts millions of Americans with diabetes who rely on this life-sustaining medication. He also shared the findings of the ADA’s “Insulin Access and Affordability Working Group: Conclusions and Recommendations” white paper, which was simultaneously published online today in the journal Diabetes Care.

Washington, DC - Remarks by President Trump on Lowering Drug Prices:

Washington, DC - Women who experience vaginal bleeding for more than one day during the first trimester of pregnancy may be more likely to have a smaller baby, compared to women who do not experience bleeding in the first trimester, suggest researchers at the National Institutes of Health. On average, full-term babies born to women with more than one day of bleeding in the first trimester were about 3 ounces lighter than those born to women with no bleeding during this time. Additionally, infants born to women with more than a day of first trimester bleeding were roughly twice as likely to be small for gestational age, a category that includes infants who are healthy but small, as well as those whose growth has been restricted because of insufficient nutrition or oxygen or other causes.

Washington, DC - A Phase 2 clinical trial of an investigational universal influenza vaccine intended to protect against multiple strains of the virus has begun in the United States. The study is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and is being conducted at four U.S. sites that are part of the NIAID-funded Vaccine and Treatment Evaluation Units (VTEUs). The trial is testing an experimental vaccine called M-001 for safety and its ability to produce potentially broad protective immune responses, both on its own and when followed by a standard, licensed seasonal influenza vaccine.

Washington, DC - Early during the recent Ebola epidemic in West Africa, scientists speculated that the genetic diversity of the circulating Makona strain of virus (EBOV-Makona) would result in more severe disease and more transmissibility than prior strains. However, using two different animal models, National Institutes of Health scientists have determined that certain mutations stabilized early during the epidemic and did not alter Ebola disease presentation or outcome. Their work, published in Cell Reports, offers further evidence to support previous findings from molecular sequencing that the diversity of EBOV-Makona did not significantly impact the course of disease.

Imperial, California - When you have pain, there's nothing you want more than relief - right now. For many people, that means reaching for the bottle of pain relievers in the medicine cabinet.